

1 **Serum but not mucosal antibody responses are associated with pre-existing**  
2 **SARS-CoV-2 spike cross-reactive CD4<sup>+</sup> T cells following BNT162b2**  
3 **vaccination in the elderly**  
4

5  
6 Lil Meyer-Arndt<sup>\*,†,‡,§,¶,1</sup>, Tatjana Schwarz<sup>||,1</sup>, Lucie Loyal<sup>\*,†</sup>, Larissa Henze<sup>\*,†</sup>,  
7 Beate Kruse<sup>\*,†</sup>, Manuela Dingeldey<sup>\*,†</sup>, Kübrah Gürcan<sup>#</sup>, Zehra Uyar-Aydin<sup>#</sup>,  
8 Marcel A. Müller<sup>||</sup>, Christian Drosten<sup>||</sup>, Friedemann Paul<sup>†,¶</sup>, Leif E. Sander<sup>\*\*</sup>, Ilja Demuth<sup>††,‡‡</sup>, Roland  
9 Lauster<sup>#</sup>, Claudia Giesecke-Thiel<sup>§§</sup>, Julian Braun<sup>\*,†,1</sup>, Victor M. Corman<sup>||,1,2</sup>, Andreas Thiel<sup>\*,†,1,2</sup>

10  
11 \* Si-M / “Der Simulierte Mensch” a science framework of Technische Universität Berlin and Charité -  
12 Universitätsmedizin Berlin, Berlin, Germany

13 † Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
14 Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH  
15 Center for Regenerative Therapies, 13353 Berlin, Germany

16 ‡ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
17 Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center,  
18 10117 Berlin, Germany

19 § Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
20 Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, 10117 Berlin,  
21 Germany

22 ¶ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
23 Universität zu Berlin, and Berlin Institute of Health, and Max Delbrueck Center for Molecular  
24 Medicine, Experimental and Clinical Research Center, Lindenberger Weg 80, 12135 Berlin, Germany

25 || Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
26 Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany

27 # Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany

28 \*\* Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-  
29 Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and  
30 Respiratory Medicine, 13353 Berlin, Germany

31 †† Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-  
32 Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of  
33 Lipid Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin,  
34 Germany

35 ‡‡ Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BCRT - Berlin Institute of Health  
36 Center for Regenerative Therapies, Berlin, Germany

37 §§ Max Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany

38  
39 <sup>1</sup> equal contribution

40  
41 <sup>2</sup> Co-Corresponding authors:

42 Andreas Thiel. Phone number: +49 30 450 539555 Email address: [andreas.thiel@charite.de](mailto:andreas.thiel@charite.de).

43 Victor M. Corman. Phone number: +49 30 450 525095. Email address: [victor.corman@charite.de](mailto:victor.corman@charite.de).

44  
45  
46  
47

48 **Abstract**

49 Advanced age is a main risk factor for severe COVID-19. However, low vaccination efficacy  
50 and accelerated waning immunity have been reported in this age group. To elucidate age-  
51 related differences in immunogenicity, we analysed human cellular, serological and salivary  
52 SARS-CoV-2 spike glycoprotein-specific immune responses to BNT162b2 COVID-19  
53 vaccine in old (69-92 years) and middle-aged (24-57 years) vaccinees compared to natural  
54 infection (COVID-19 convalescents, 21-55 years). Serological humoral responses to  
55 vaccination exceeded those of convalescents but salivary anti-spike subunit 1 (S1) IgA and  
56 neutralizing capacity were less durable in vaccinees. In old vaccinees, we observed that pre-  
57 existing spike-specific CD4<sup>+</sup> T cells are associated with efficient induction of anti-S1 IgG and  
58 neutralizing capacity in serum but not saliva. Our results suggest pre-existing SARS-CoV-2  
59 cross-reactive CD4<sup>+</sup> T cells as predictor of an efficient COVID-19 vaccine-induced humoral  
60 immune response in old individuals.

61

62

63

64

65

66

67

68

69

70

71

72

73

74 **Introduction**

75 Global efforts have been mounted to develop efficient vaccines against coronavirus disease  
76 2019 (COVID-19) (1). As severe COVID-19 mainly affects older individuals, many  
77 vaccination campaigns have prioritized the elderly population (2). However, vaccination  
78 efficacy is known to be decreased in this age group, particularly for primary vaccination (3).  
79 For COVID-19 vaccination - given the distinct homology of certain antigen target regions of  
80 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to human common cold  
81 coronaviruses (HCoV) - one possible explanation could be an age-related reduced number of  
82 pre-existing cross-reactive CD4<sup>+</sup> T cells in old individuals (4, 5). To assess the  
83 immunogenicity of the COVID-19 vaccine in this particularly vulnerable age group and  
84 identify possible relations to pre-existing SARS-CoV-2-specific cross-reactivities, we  
85 examined systemic cellular and serological and salivary humoral SARS-CoV-2-specific  
86 immunity during the course of COVID-19 vaccination with BNT162b2 mRNA vaccine  
87 (Tozinameran™, Comirnaty™) in old and comorbid nursing home residents (n=18; mean age  
88 83±6) and their middle-aged caregivers (n=14; mean age 47±10) at baseline (prior to first  
89 vaccination), at day 28 (d28, 7 days after second vaccination) and at day 49 (d49, 28 days  
90 after second vaccination). For comparison with naturally acquired immunity, we additionally  
91 analysed COVID-19 convalescents (of comparable age to the middle-aged cohort; mean age  
92 36±11) after mild natural SARS-CoV-2 infection at ~d28 (n=10), ~d49 (n=16) or ~d94  
93 (n=11) after symptom onset.

94

95

96

97

98

99

## 100 **Materials and Methods**

### 101 **Participants and ethics**

102 The study was approved by the ethics committee of Charité – Universitätsmedizin Berlin  
103 (EA/152/20) and was conducted in accordance with the World Medical Association’s  
104 Declaration of Helsinki of 1964 and its later amendments. A written informed consent was  
105 obtained from all participants. The 39 participants (22 nursing home residents (old vaccinees),  
106 17 caregivers (middle-aged vaccinees), all Caucasian) analysed for this study were  
107 recruited at three different nursing homes in Berlin between September and November 2020  
108 and were available for follow-up visits 28 days and 49 days after their first COVID-19  
109 vaccination in January and February 2021 (Table I). Furthermore, we collected saliva and  
110 blood samples of a total of 36 COVID-19 convalescents with mild disease course (World  
111 Health Organisation criteria for COVID-19 II) at ~28 (n=10), ~49 (n=16) or ~94 days (n=11)  
112 post symptom onset. Baseline data of vaccinees and data of convalescents had been collected  
113 and partially analysed as part of the Charité Corona Cross (CCC) study (4). Visits included  
114 nasopharyngeal swabs, blood and saliva sampling at all time points. None of the participants  
115 took immunomodulating medication or reported immunocompromising comorbidities. 4 older  
116 and 3 middle-aged donors with signs of previous SARS-CoV-2 infection (either positive anti-  
117 S1 IgG levels or a S-I T cell stimulation index > 3.0 at baseline) were excluded from analysis.

118

### 119 **SARS-CoV-2 RT-PCR**

120 Nasopharyngeal swabs were suspended in 4.3 ml Cobas PCR Media. RNA was extracted  
121 using the MagNA Pure 96 system (Roche). The viral RNA extraction was performed using  
122 200 µl swab dilution eluted in 100 µl of extraction buffer. SARS-CoV-2 detection was based  
123 on two genomic targets (E- and N gene, TIB Molbiol) using 5 µl of the RNA eluate.  
124 Quantification of SARS-CoV-2 copy numbers was achieved using calibration curves with  
125 serial diluted photometrically quantified in-vitro transcribed RNA as described before

126 (6). RT-PCR was performed using the LightCycler 480 II (Roche). Vaccinees who tested  
127 positive by RT-PCR in the study period (n=2) were excluded from all analyses.

128

### 129 **Blood sampling, serum preparation and PBMC isolation**

130 Whole blood was collected in lithium heparin tubes for PBMC isolation and SST™II advance  
131 (all Vacutainer®, BD) tubes for serology. SST™II advance tubes were centrifuged at 1000 x  
132 g, 10 min and serum supernatant aliquots frozen at -80 °C until further use. PBMC were  
133 isolated by gradient density centrifugation according to the manufacturer's instructions  
134 (Leucosep tubes, Greiner; Biocoll, Bio&SELL).

135

### 136 **Ex vivo T cell stimulation and flow cytometry**

137 T cell in vitro stimulation and subsequent flow cytometric assessment of reactive CD4<sup>+</sup> T  
138 cells was performed as described in detail previously (4). In brief, freshly isolated PBMC  
139 were stimulated with 11aa overlapping 15-mer PepMix™ SARS-CoV-2 spike glycoprotein  
140 peptide pool 1 or 2 (termed here S-I and S-II; JPT) or remained unstimulated and were  
141 subsequently incubated at 37 °C for 16 h. Surface staining was performed with the following  
142 fluorochrome-conjugated antibodies titrated to their optimal concentrations: CD3-FITC  
143 (REA613, Miltenyi), CD4-VioGreen (REA623, Miltenyi), CD8-VioBlue (REA734,  
144 Miltenyi), CD38-APC (REA671, Miltenyi), HLA-DR-PerCpVio700 (REA805, Miltenyi).  
145 Fixation and permeabilization were performed with eBioscience™ FoxP3 fixation and  
146 PermBuffer (Invitrogen). Intracellular staining was carried out for 30 min in the dark at room  
147 temperature with 4-1BB-PE (REA765, Miltenyi) and CD40L-PE-Vio770 (REA238,  
148 Miltenyi). All samples were measured on a MACSQuant® Analyzer 16 (Miltenyi) according  
149 to the gating strategy illustrated in Supplemental Fig. 1.

150

151

152 **Anti-SARS-CoV-2 S1 ELISA in serum and saliva**

153 Anti-SARS-CoV-2 spike glycoprotein subunit 1 (S1) IgG and IgA testing in  
154 sera was performed using a commercially available ELISA kit (Euroimmun) as previously  
155 described (7). Test results for sera were considered positive above an OD ratio (defined as  
156 absorbance difference between control and study sample) of 1.1 according to the  
157 manufacturer. The same ELISA kit was used for anti-SARS-CoV-2 IgA testing in saliva. The  
158 assay was performed with 1:100 diluted serum and 1:10 diluted saliva. Values were capped at  
159 an OD ratio of 10. Positivity thresholds have not yet been determined for saliva.

160

161 **Surrogate virus neutralization assay (sVNT)**

162 A competition ELISA-based surrogate virus neutralization assay (sVNT; medac) mimicking  
163 the SARS-CoV-2 receptor (ACE2) binding process was used to identify neutralizing anti-  
164 SARS-CoV-2 antibodies in participant serum and saliva (8, 9). The assay was performed with  
165 1:10 diluted serum and 1:5 diluted saliva respectively following the manufacturer's  
166 instructions. Inhibition activity above 30% was considered positive in serum, no threshold has  
167 been defined for saliva yet.

168

169 **Data processing and statistical analysis**

170 Study data were collected and managed using REDCap electronic data capture tools hosted at  
171 Charité (10). Flow cytometry data were analysed using FlowJo 10 (BD). Prism 9  
172 (GraphPad) was used for data plotting. For statistical comparisons and correlation analyses,  
173 non-parametric testing (Mann-Whitney U test or Spearman regression including ROUT  
174 outlier tests) were performed. Mann-Whitney U tests were performed between corresponding  
175 timepoints if not indicated differently. Statistical significance was reported as follows: \*p  
176  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*p  $\leq 0.001$ . Correlation coefficients of Spearman correlations were  
177 reported as r. CD4<sup>+</sup> T cell activation was plotted as stimulation index (Stimulation Index), i.e.

178 frequency of CD40L<sup>+</sup>4-1BB<sup>+</sup> CD4<sup>+</sup> T cells in stimulated samples divided by unstimulated  
179 controls (zero background values were set to a minimum of 0.001).

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

## 204 **Results and Discussion**

205 In this study, we investigated age-related differences in systemic and mucosal immune  
206 responses to COVID-19 mRNA vaccine BNT162b2 and compared to COVID-19  
207 convalescents. First, we analysed anti-S1 IgG and anti-S1 IgA antibody levels and S1  
208 neutralization capacity in serum as well as frequencies of peripheral antigen-reactive CD40L<sup>+</sup>  
209 4-1BB<sup>+</sup> CD4<sup>+</sup> T cells after *in vitro* stimulation with the N-terminal part (S1, covered by  
210 peptide mix S-I) and the C-terminal part (S2, peptide mix S-II) of the spike glycoprotein (Fig.  
211 1a-e). In middle-aged donors, BNT162b2 vaccination induced a prompt and homogeneous  
212 response of anti-S1 IgG, anti-S1 IgA, S1-specific functional neutralization in serum and  
213 spike-reactive CD4<sup>+</sup> T cells. In comparison, we observed significantly lower anti-S1 IgG and  
214 anti-S1 IgA levels and S1 neutralizing capacity in serum at both time points and lower T cell  
215 reactivity to S-I and S-II at ~d49 in COVID-19 convalescents of comparable age after mild  
216 infection, which underlines the strong immunogenicity of BNT162b2 vaccine (Fig. 1a-e).  
217 However, in old vaccinees, particularly humoral vaccination responses were delayed and  
218 more heterogeneously distributed compared to the middle-aged cohort (Fig. 1a-e). For  
219 example, at d28, we did not detect anti-S1 IgG and anti-S1 IgA in five (28%) and eight (44%)  
220 old donors respectively (Fig. 1a and b; Supplemental Fig. 2) whereas all middle-aged donors  
221 exhibited strongly positive anti-S1 IgG levels. At d49, anti-S1 IgG and S1 neutralizing  
222 capacity (including one non-responder) were still significantly lower in the old vaccinees  
223 (Fig. 1a and c). Regarding the cellular response, all middle-aged and 89% (S-I) and 94% (S-  
224 II) respectively of the old donors acquired CD4<sup>+</sup> T cell reactivity to S-I and S-II at d28.  
225 However, S-II-reactive T cell frequencies increased more homogeneously and reached a higher  
226 level in the middle-aged than in the old cohort. At d49, both age groups reached comparable  
227 S-I- and S-II-reactive T cell levels (Fig. 1d-e). Consistently, reduced humoral and cellular  
228 vaccination responses in old individuals have been described for vaccines against influenza,  
229 yellow fever and tetanus as well as for COVID-19 (12-15).



230 We have recently demonstrated that, in contrast to the N-terminal part, the C-terminal part of  
231 the spike glycoprotein contains highly conserved domains and triggers CD4<sup>+</sup> T cell cross-  
232 reactivity to SARS-CoV-2 (11). Pre-existing T cell reactivity to S-II at baseline was  
233 significantly lower in old individuals than in the middle-aged cohort (Fig. 1e; Supplemental  
234 Fig. 3a). Possible explanations for this age-related reduction of cross-reactivity could be  
235 cellular senescence or impaired (oronasal) mucosal immunity (16-18). Remarkably though, in  
236 these old individuals, high levels of S-II-specific, but not S-I-specific, CD4<sup>+</sup> T cells at  
237 baseline were associated with higher anti-S1 IgG and consistently with elevated S1  
238 neutralizing capacity in serum at d28 (Fig. 1f-g; Supplemental Fig. 3b). In the light of the  
239 increased risk of the elderly for severe COVID-19 and the current discussions on their need of  
240 booster vaccinations, it is essential to identify and evaluate possible predictors of low  
241 vaccination efficiency particularly in this age group. Several studies have supported the  
242 notion of beneficial effects of pre-exposure SARS-CoV-2 cross-reactivity (4, 19, 20).  
243 However, whether this phenomenon has a direct effect on BNT162b2 immunogenicity in the  
244 elderly was unclear. Our findings here show that increased frequencies of pre-existing S-II-  
245 specific CD4<sup>+</sup> T cells were associated with the efficiency of anti-S1 IgG and S1 neutralizing  
246 vaccination responses in the elderly. Cross-reactive CD4<sup>+</sup> memory T cells expand faster upon  
247 antigen reactivation post-vaccination to aide B cell activation and class-switch and thus mount  
248 a more efficient antibody response.

249 We additionally investigated the presence of anti-S1 secretory IgA (sIgA) and S1  
250 neutralization capacity in the saliva as a potential correlate of local mucosal protection from  
251 SARS-CoV-2 infection. We assume that the presence of S1-specific antibodies and S1  
252 neutralizing capacity in the saliva may contribute to protection against SARS-CoV-2 infection  
253 and reduce local replication (21, 22). At d28 following vaccination, anti-S1 sIgA levels  
254 increased above their age groups' maximum pre-vaccination level in all middle-aged (0.45  
255 OD ratio) but only 60% of the old donors (0.31 OD ratio; Fig. 2a). Consistently, an increase

256 in S1 neutralizing activity in saliva was detected in most vaccinees at d28 (Fig. 2b). This  
257 response, however, was transient and anti-S1 sIgA and salivary S1 neutralization dropped to  
258 pre-vaccination levels in all vaccinees within four weeks (d49) after the second vaccination  
259 (Fig. 2a and b). There was no correlation between anti-S1 sIgA or salivary S1 neutralizing  
260 capacity and pre-existing cross-reactive CD4<sup>+</sup> T cells (Fig. 2c and d). Intriguingly, compared  
261 to aged-matched middle-aged vaccinees, COVID-19 convalescents exhibited significantly  
262 higher anti-S1 sIgA levels and S1 neutralizing capacity in the saliva at ~d49 after symptom  
263 onset (Fig. 2a and b). Unlike salivary S1 neutralizing capacity, anti-S1 sIgA remained  
264 significantly increased in convalescents at ~d94 indicating that anti-S1 sIgA does not  
265 correspond to neutralizing activity following infection at later time points. However, we  
266 found a correlation between anti-S1 sIgA levels and salivary S1 neutralization in  
267 convalescents at ~d28 and at ~d49, which was not observed in vaccinees (Supplemental Fig.  
268 4). This suggests that neutralizing capacity in the saliva following vaccination may not only  
269 rely on anti-S1 sIgA but possibly anti-S1 IgG, which is consistent with reports on detectable  
270 anti-S1 IgG in the saliva of vaccinated individuals (23). In COVID-19 convalescents, anti-S1  
271 sIgA secretion in salivary glands (and salivary S1 neutralizing activity) is likely induced by  
272 locally primed B and T cells in nasopharyngeal lymph nodes and/or tonsils (24). This is  
273 underlined by an increase in salivary neutralization capacity and sIgA in convalescents from  
274 d28 to d49 after infection (Fig. 2a and b) and may indicate generation of tissue-resident  
275 plasma cells after mucosal priming. In contrast, the more transient presence of anti-S1 sIgA in  
276 the saliva of vaccinated individuals could be the result of transfusion of serum-derived anti-S1  
277 IgA through the endothelium into the oral mucosa (25). Currently, vaccines for intranasal  
278 application are in development, which may fill the gap in mucosal immunity observed here  
279 (26).

280 Taken together, our findings indicate that the presence of anti-S1 sIgA and S1 neutralizing  
281 capacity in the saliva after vaccination is of shorter duration and lower magnitude than after

282 natural infection highlighting the need to determine the role of mucosal immunity, e.g., in the  
283 form of sIgA in saliva, for evaluation of SARS-CoV-2 immunity and its transmission.  
284 Furthermore, we demonstrate that BNT162b2 induces strong immune responses in middle-  
285 aged as well as most old and comorbid individuals. However, for some old individuals, the  
286 serological response to vaccination is hampered and may leave these individuals at higher risk  
287 of infection and severe disease courses, thus promoting recommendations for regular immune  
288 status check-ups and further vaccination boosts. Importantly, we show here that pre-existing  
289 SARS-CoV-2 spike glycoprotein cross-reactive memory T cells are associated with  
290 vaccination efficiency in the elderly and may generally contribute to the high responsiveness  
291 to COVID-19 vaccines.  
292

293 **Acknowledgments and Funding**

294 We thank the CCC Study Group.

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319 **References**

- 320 1. Krammer, F. 2020. SARS-CoV-2 vaccines in development. *Nature*. 586(7830), 516-  
321 527.
- 322 2. Zheng, Z., F. Peng, B. Xu, J. Zhao, H. Liu, J. Peng, Q. Li, C. Jiang, Y. Zhou, S. Liu,  
323 C. Ye, P. Zhang, Y. Xing, H. Guo, and W. Tang. 2020. Risk factors of critical &  
324 mortal COVID-19 cases: A systemic literature review and meta-analysis. *J Infect*.  
325 81(2).
- 326 3. Siegrist, A.-C. and R. Aspinall. 2009. B-cell responses to vaccination at the extremes  
327 of age. *Nat Rev Immunol*. 9(3), 185-94.
- 328 4. Loyal, L., J. Braun, L. Henze, B. Kruse, M. Dingeldey, U. Reimer, F. Kern, T.  
329 Schwarz, M. Mangold, C. Unger, F. Dörfler, S. Kadler, J. Rosowski, K. Gürcan, Z.  
330 Uyar-Aydin, M. Frentsch, F. Kurth, K. Schnatbaum, M. Eckey, S. Hippenstiel, A.  
331 Hocke, M. A. Müller, B. Sawitzki, S. Miltenyi, F. Paul, M. A. Mall, H. Wenschuh, S.  
332 Voigt, C. Drosten, R. Lauster, N. Lachmann, L. E. Sander, V. M. Corman, J. Röhmel,  
333 L. Meyer-Arndt, A. Thiel, and C. Giesecke-Thiel. 2021. Cross-reactive CD4<sup>+</sup> T cells  
334 enhance SARS-CoV-2 immune responses upon infection and vaccination. *Science*.  
335 373, 6558.
- 336 5. Saletti, G., T. Gerlach, J. M. Jansen, A. Molle, H. Elbahesh, M. Ludlow, M. Li, B.-J.  
337 Bosch, A. C. M. E. Osterhaus, and G. F. Rimmelzwaan. 2020. Older adults lack SARS  
338 CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and  
339 NL63. *Sci Rep*. 10(1), 21447.
- 340 6. Corman, V. M., O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. Kw Chu, T.  
341 Bleicker, S. Brünink, J. Schneider, M. L. Schmidt, D. Gjc Mulders, B. L. Haagmans,  
342 B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J.-L. Romette, J. Ellis,  
343 M. Zambon, M. Peiris, H. Goossens, C. Reusken, M. Pg Koopmans, and C. Drosten.

- 344 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro*  
345 *Surveill* 25(3), 2000045.
- 346 7. Okba, N. M. A., M. A. Müller, W. Li, C. Wang, C. H. Geurts van Kessel, V. M.  
347 Corman, M. M. Lamers, R. S. Sikkema, E. de Bruin, F. D. Chandler, Y. Yazdanpanah,  
348 Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh, C. B. E. M. Reusken, B.-J. Bosch,  
349 C. Drosten, M. P. G. Koopmans, and B. L. Haagmans. 2020. Severe Acute  
350 Respiratory Syndrome Coronavirus 2 – Specific Antibody Responses in Coronavirus  
351 Disease Patients. *Emerg Infect Dis.* 26(7), 1478-1488.
- 352 8. Von Rhein, C., T. Scholz, L. Henss, R. Kronstein-Wiedemann, T. Schwarz, R. N.  
353 Rodionov, V. M. Corman, T. Tonn, and B. S. Schnierle. 2021. Comparison of potency  
354 assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19  
355 convalescent plasma. *J Virol Methods.* 288:114031.
- 356 9. Tan, C. W., W. Ni Chia, X. Qin, P. Liu, M. I.C. Chen, C. Tiu, Z. Hu, V. Chih-Wei  
357 Chen, B. E. Young, W. Rong Sia, Y.J. Tan, R. Foo, Y. Yi, D. C. Lye, D. E. Anderson  
358 and L.-F. Wang. 2020. A SARS-CoV-2 surrogate virus neutralization test based on  
359 antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat*  
360 *Biotechnol.* 38(9):1073-1078.
- 361 10. Harris, P. A., R. Taylor, B. L. Minor, V. Elliott, M. Fernandez, L. O’Neal, L. McLeod,  
362 G Delacqua, F. Delacqua, J. Kirby, S. N. Duda, and REDCap Consortium. 2019. The  
363 REDCap consortium: Building an international community of software platform  
364 partners. *J Biomed Inform.* 95, 103208.
- 365 11. Braun J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S Hippenstiel, M.  
366 Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M.  
367 A. Mall, K. Beyer, J. Röhmel, S. Voigt, J. Schmitz, S. Miltenyi, I. Demuth, M. A.  
368 Müller, A. Hocke, M. Witzenrath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C.  
369 Drosten, V. M. Corman, C. Giesecke-Thiel, L. E. Sander, and A. Thiel. 2020. SARS-

- 370 CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature*.  
371 587(7833), 270-274.
- 372 12. Schatz, D., T. Ellis, E. Ottendorfer, E. Jodoin, D. Barrett, and M. Atkinson. 1998.  
373 Aging and the Immune Response to Tetanus Toxoid: Diminished Frequency and  
374 Level of Cellular Immune Reactivity to Antigenic Stimulation. *Clin Diagn Lab*  
375 *Immunol.* 5(6):894-6.
- 376 13. Schulz, A.R., J. N. Mälzer, C. Domingo, K. Jürchott, A. Grützkau, N. Babel, M.  
377 Nienen, T. Jelinek, M. Niedrig, and A. Thiel. 2015. Low Thymic Activity and  
378 Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral  
379 Infection in Elderly Humans. *J Immunol.* 195(10):4699-711.
- 380 14. Jürchott, K., A. R. Schulz, C. Bozzetti, D. Pohlmann, U. Stervbo, S. Warth, J. N.  
381 Mälzer, J. Waldner, B. Schweiger, S. Olek, A. Grützkau, N. Babel, A. Thiel, and A. U.  
382 Neumann. 2016. Highly Predictive Model for a Protective Immune Response to the  
383 A(H1N1)pdm2009 Influenza Strain after Seasonal Vaccination. *PLoS One.* 8;11(3).
- 384 15. Collier, D. A., I. A. T. M. Ferreira, P. Kotagiri, R. P. Datir, E. Y. Lim, E. Touizer, B.  
385 Meng, A. Abdullahi, A. Ellmer, N. Kingston, B. Graves, E. Le Gresley, D. Caputo, L.  
386 Bergamaschi, K. G. C. Smith, J. R. Bradley, L. Ceron-Gutierrez, P. Cortes-Acevedo,  
387 G. Barcenas-Morales, M. A. Linterman, L. E. McCoy, C. Davis, E. Thomson, P. A.  
388 Lyons, E. McKinney, R. Doffinger, M. Wills, R. K. Gupta. 2021. Age-related immune  
389 response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature.* 596(7872):417-  
390 422-
- 391 16. Aiello, A., F. Farzaneh, G. Candore, C. Caruso, S. Davinelli, C. M. Gambino, M. E.  
392 Ligotti, N. Zareian, and G. Accardi. 2019. Immunosenescence and its hallmarks: How  
393 to oppose aging strategically? A review of potential options for therapeutic  
394 intervention. *Front Immunol.* 10, 2247.

- 395 17. Heaney, J. L. J., A. C. Phillips, D. Carroll, and M. T. Drayson. 2015. Salivary  
396 Functional Antibody Secretion Is Reduced in Older Adults: A Potential Mechanism of  
397 Increased Susceptibility to Bacterial Infection in the Elderly. *J Gerontol A Biol Sci*  
398 *Med Sci.* 70(12):1578-85.
- 399 18. Sato, S., H. Kiyono, and K. Fujihashi. 2015. Mucosal Immunosenescence In The  
400 Gastrointestinal Tract. *Gerontology.* 61(4):336-42.
- 401 19. Mateus, J., J. M. Dan, Z. Zhang, C. Rydyznski Moderbacher, M. Lammers, B.  
402 Goodwin, A. Sette, S. Crotty, and D. Weiskopf. 2021. Low-dose mRNA-1273  
403 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.  
404 *Science.* doi: 10.1126/science.abj9853.
- 405 20. Niessl, J., T. Sekine, J. Lange, V. Konya, M. Forkel, J. Maric, A. Rao, L. Mazzurana,  
406 E. Kokkinou, W. Weigel, S. Llewellyn-Lacey, E. B. Hodcroft, A. C. Karlsson, J.  
407 Fehrm, J. Sundman, D. A. Price, J. Mjösberg, D. Friberg, and M. Buggert. 2021.  
408 Identification of resident memory CD8<sup>+</sup> T cells with functional specificity for SARS-  
409 CoV-2 in unexposed oropharyngeal lymphoid tissue. *Sci Immunol.* doi:  
410 10.1126/sciimmunol.abk0894.
- 411 21. Renegar, K. B., P. A. Small Jr., L. G. Boykins, and P. F. Wright. 2004. Role of IgA  
412 versus IgG in the control of influenza viral infection in the murine respiratory tract. *J*  
413 *Immunol.* 173(3), 1978-86.
- 414 22. Mantis, N. J., and S. J. Forbes. 2010. Secretory IgA: Arresting microbial pathogens at  
415 epithelial borders. *Immunol Invest.* 39(0), 383-406.
- 416 23. Sterlin, D., A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Clear, P. Quentric, J.  
417 Fadlallah, H. Devilliers, P. Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot,  
418 C.-E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Bruel, O. Schwartz, J.-M. Lacorte,  
419 H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, and G. Gorochov. 2021.



420 IgA dominates the early neutralizing antibody response to SARS-CoV-2.  
421 *Sci Transl Med.* 13(577), 2223.

422 24. Zuercher, A. W., S. E. Coffin, M. C. Thurnheer, P. Fundova, and J. J. Cebra. 2002.  
423 Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific  
424 humoral and cellular immune responses. *J Immunol.* 168(4), 1796-803.

425 25. Langereis, J. D., J. F. M. Jacobs, M. I. de Jonge, and M. van Deuren. 2019. Plasma  
426 therapy leads to an increase in functional IgA and IgM concentration in the blood and  
427 saliva of a patient with X-linked agammaglobulinemia. *J Transl Med.* 17(1), 174.

428 26. Lund, F. E. and T. D. Randall. 2021. Scent of a vaccine. *Science.* 373(6553):397-399.

429

#### 430 **Abbreviations**

431 COVID-19, coronavirus disease 2019

432 d28, day 28 after first vaccination

433 d49, day 49 after first vaccination

434 ~d28, around day 28 after COVID-19 symptom onset

435 ~d49, around day 49 after COVID-19 symptom onset

436 ~d94, around day 94 after COVID-19 symptom onset

437 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

438 sIgA, secretory IgA

439 sVNT, surrogate virus neutralization assay

440 S1, SARS-CoV-2 spike glycoprotein subunit 1

441 S-I, peptide mix representing the SARS-CoV-2 spike glycoprotein N-terminal part

442 S-II, peptide mix representing the SARS-CoV-2 spike glycoprotein C-terminal part mix

443

444

445

446

447

448

449

450

451 **Figure Legends**

452

453 **Fig. 1: Serological antibody responses, neutralizing capacity and CD4<sup>+</sup> T cell reactivity**

454 **to S-I and S-II. a and b**, anti-S1 serum IgG (**a**) and IgA (**b**) OD ratios in the old (red dots)

455 and middle-aged (white) vaccinees at BL, d28 and d49 and in COVID-19 convalescents

456 (blue) at ~d28 or ~d49. **c**, quantification of SARS-CoV-2 receptor (ACE2) binding inhibition

457 in serum in percent in the old and middle-aged vaccinees at BL, d28 and d49 and in COVID-

458 19 convalescents at ~d28 or ~d49. **d and e**, Stimulation Indices of S-I (**d**) and S-II (**e**) peptide

459 pool-specific CD40L<sup>+</sup> 4-1BB<sup>+</sup> CD4<sup>+</sup> T cells in the old and middle-aged vaccinees at baseline

460 (BL), d28 and d49 and in COVID-19 convalescents at ~d28 or ~d49. **f and g**, anti-S1 serum

461 IgG OD ratios (**f**) and inhibition in serum (**g**) in the old and middle-aged vaccinees at d28

462 grouped according to S-II-specific CD4<sup>+</sup> T cell reactivity at BL (Stimulation Index > 1.5).

463 Positivity thresholds: antibody OD ratio (dotted lines) > 1.1; neutralizing capacity (dotted

464 lines) > 30%; CD4<sup>+</sup> T cells Stimulation Index (dotdash lines) > 1.5 (positive, above

465 background) and (dashed lines) > 3.0 (certainly positive; 6). Grey lines connect follow-up

466 samples.  $p \leq 0.05 = *$ ,  $p \leq 0.01 = **$ ,  $p \leq 0.001 = ***$ ,  $p \leq 0.0001 = ****$  according to the Mann-

467 Whitney U test.

468

469 **Fig. 2: Salivary immune responses.**

470 **a**, anti-S1 saliva sIgA OD ratios in the old (red dots) and middle-aged (white) vaccinees at

471 BL, d28 and d49 and in COVID-19 convalescents (blue) at ~d28, ~d49 or ~d94. **b**,

472 quantification of SARS-CoV-2 receptor (ACE2) binding inhibition in saliva in percent in the  
473 old and middle-aged vaccinees at BL, d28 and d49 and in COVID-19 convalescents at ~d28,  
474 ~d49 or ~d94. **c and d**, anti-S1 saliva sIgA OD ratios (**c**) and inhibition in saliva (**d**) in the old  
475 and middle-aged vaccinees at d28 grouped according to S-II-specific CD4<sup>+</sup> T cell reactivity at  
476 BL (Stimulation Index > 1.5). Salivary anti-S1 sIgA and ACE2 binding inhibition are  
477 displayed as means of up to three saliva samples on consecutive days (one per day for three  
478 days). Grey lines connect follow-up samples. ns = non-significant,  $p \leq 0.05 = *$ ,  $p \leq 0.01 = **$ ,  
479  $p \leq 0.001 = ***$  according to the Mann-Whitney U-test.

480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514

515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527

**Tables**

528 **Table I.** Donor characteristics.

<b>Cohort</b>	<b>Number (#)</b>	<b>Sex (female)</b>	<b>Mean age in years [SD]</b>	<b>Mean # of days between symptom onset and testing [SD]</b>
Vaccinated elderly	18	11	82.56 [5.82]	
Vaccinated middle-aged	14	13 *	47.36 [10.10] ****	
COVID-19 convalescents (unvaccinated) ~d28 after symptom onset	10	6	33.8 [10.32]	27.2 [5.01]
COVID-19 convalescents (unvaccinated) ~d49 after symptom onset	16	12	34.94 [11.53]	49.19 [6.45]
COVID-19	11	6	39.40 [10.67]	93.90 [9.02]

convalescents (unvaccinated) ~d94 after symptom onset				
--	--	--	--	--








529 SD = standard deviation. Significance of statistical differences in demographic parameters

530 between middle-aged and elderly vaccinees is displayed by \*, \*\*, \*\*\*, \*\*\*\*.

531

**Figure 1**

● Old    ○ Middle-aged    ● Convalescents

**a****b****c****d****e****f****g**

# Figure 2

